Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary Proteomics in Obese Hypertensive Patients (PREDICT-HTN)
NCT06208072Recruiting
- Sponsor
- Hippocration General Hospital
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial in primary hypertension comparing Irbesartan group with Eplerenone group (2 arms). Primary endpoints: Urinary peptide differential expression between responders and non-responders in patients treated with Irbesartan at 8 weeks and Urinary peptide differential expression between responders and non-responders in patients treated with Eplerenone at 8 weeks. Started Sep 2023; status: recruiting.
02
Drugs
irbesartaneplerenone
03
Conditions
primary hypertension
Beyond the preview
Go deeper on NCT06208072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208072.